Probiotic

A probiotic safely reduced Staphylococcus aureus colonization in a phase 2 human trial without harming other gut microbiota, suggesting a potential approach to preventing infection without using antibiotics.

As asthma affects significant proportions of the population, research strove to improve the lives of these patients in 2022. Here are Healio’s 10 most popular stories about these developments.

Low bacterial diversity and Bifidobacterium depletion were associated with severely symptomatic COVID-19 infection in a small subset of patients — a pattern of dysbiosis that may serve as a susceptibility marker for symptomatic severity.

Probiotic lozenges relieved symptoms of allergic rhinitis for at least a week after the end of treatment with minimal or no side effects during a single-center, 21-day interventional study, according to a press release.

Women who took a probiotic supplement for bothersome vaginal odor and symptoms such as irritation and painful urination reported substantial improvements within 2 weeks, according to study findings presented at the NAMS Annual Meeting.

Probiotic supplements such as Bifidobacterium infantis 35624 could improve asthma control and lung function while reducing the need to use rescue inhalers, according to a letter published in Annals of Allergy, Asthma & Immunology.

In the age of the internet and social media, one thing we can always count on is having access to a lot of information. But what happens when that information is not entirely accurate and does more damage than good?

Supplementation with a mixture of two probiotics may prevent asthma exacerbations among children with allergy, particularly those with house dust mite allergies, according to a study published in Annals of Allergy, Asthma & Immunology.

Patients with stage 3 to 4 chronic kidney disease prefer prebiotic and probiotic supplements that are flexible and easily integrated into daily routines, according to data published in the Journal of Renal Nutrition.

In this video, Sumanta K. Pal, MD, discusses updates from a clinical trial on the use of nivolumab/ipilimumab with and without a probiotic agent in patients with metastatic renal cell carcinoma.